Introduction: Evidence for the role of inflammation in benign prostatic hyperplasia (BPH) is conflicting. Establishing the prognostic significance of local and systemic inflammation and tissue necrosis scoring systems in BPH may elucidate the potential of inflammatory pathways as a target of therapeutic intervention in these patients. Patients and Methods: Consecutive patients with histological BPH diagnosed between 1996 and 2005 were identified. Systemic inflammation was assessed by the modified Glasgow prognostic score (mGPS), local inflammation by the Klintrup-Makinen criteria and tissue necrosis was evaluated by an extent-based classification. Results: In 392 BPH patients, there was a trend for increased local inflammation and tissue necrosis to be associated with shorter time to failure of pre-operative medical treatment of BPH (p = 0.096 and 0.088, respectively). High modified Glasgow prognostic score was associated with older age (p = 0.002) and higher levels of deprivation (measured by the Scottish Index of Multiple Deprivation) (p = 0.021). Conclusions: The prognostic use of established scoring systems of systemic and local inflammation and tissue necrosis in BPH requires further investigation. It remains unclear as to whether targeting inflammation in BPH has therapeutic potential.

Keywords:
Benign prostatic hyperplasia, Lower urinary tract symptoms, Inflammation
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
2.
De Nunzio C, Kramer G, Marberger M, et al: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106-117.
3.
Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA: Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005;62:27-33.
4.
Liao CH, Chung SD, Kuo HC: Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. Urology 2011;78:1373-1378.
5.
Kohnen PW, Drach GW: Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979;121:755-760.
6.
Di Silverio F, Gentile V, De Matteis A, et al: Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003;43:164-175.
7.
Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M: Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004;60:153-159.
8.
Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP: Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplastic, and malignant human prostate. J Pathol 2004;202:41-49.
9.
Tuncel A, Uzun B, Eruyar T, Karabulut E, Seckin S, Atan A: Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol 2005;48:277-283, discussion 283-284.
10.
Choong S, Emberton M: Acute urinary retention. BJU Int 2000;85:186-201.
11.
Qayyum T, McArdle PA, Going JJ, et al: Is the presence or absence of tumour necrosis a significant predictor of survival in renal cell cancer? Urol Int 2012;88:79-83.
12.
Klintrup K, Makinen JM, Kauppila S, et al: Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645-2654.
13.
Roxburgh CS, McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-163.
14.
Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS: Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 2012;15:195-201.
15.
Kramer G, Steiner GE, Handisurya A, et al: Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52:43-58.
16.
Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC: Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009;45:2138-2145.
17.
Lamb AD, Qadan M, Roberts S, et al: CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia. BJU Int 2011;108:E43-E50.
18.
Robert G, Descazeaud A, Nicolaiew N, et al: Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009;69:1774-1780.
19.
Schenk JM, Kristal AR, Neuhouser ML, et al: Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2012;171:571-582.
20.
St Sauver JL, Sarma AV, Jacobson DJ, et al: Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009;169:1281-1290.
21.
Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
22.
Anjum I, Ahmed M, Azzopardi A, Mufti GR: Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia. J Urol 1998;160:792-793.
23.
Jacobsen SJ, Jacobson DJ, Girman CJ, et al: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-487.
24.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-2400.
25.
Leibovich BC, Blute ML, Cheville JC, et al: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-1671.
26.
Klatte T, Said JW, de Martino M, et al: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol 2009;181:1558-1564.
27.
Spiro LH, Labay G, Orkin LA: Prostatic infarction. Role in acute urinary retention. Urology 1974;3:345-347.
28.
Baird HH, McKay HW, Kimmelstiel P: Ischemic infarction of the prostate gland. South Med J 1950;43:234-240.
29.
Abeshouse BS: Infarct of the prostate. J Urol 1933;30:97.
30.
Strachan JR, Corbishley CM, Shearer RJ: Post-operative retention associated with acute prostatic infarction. Br J Urol 1993;72:311-313.
31.
Jones TJ, Howie AJ: Necropsy study of infarcts of prostate and prostatic urethra. J Clin Pathol 1986;39:1221-1223.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.